What is the recommended dosage and treatment guidelines for Tamiflu (oseltamivir) in patients with influenza?

Tamiflu (Oseltamivir) Dosing and Treatment Guidelines

Treatment Dosing

Oseltamivir 75 mg orally twice daily for 5 days is the standard treatment for adults and adolescents ≥13 years with influenza, and treatment should be initiated within 48 hours of symptom onset for maximum benefit. 1, 2

Adults and Adolescents (≥13 years)

• 75 mg orally twice daily for 5 days 1, 2
• Can be taken with or without food, though administration with meals improves gastrointestinal tolerability 1, 3
• Treatment initiated within 12 hours of fever onset reduces illness duration by 3.1 days (41%) compared to treatment at 48 hours 4
• Earlier treatment progressively increases therapeutic benefit at every time point 4, 5

Pediatric Patients (≥12 months) - Weight-Based Dosing

All doses given twice daily for 5 days: 1, 2

• ≤15 kg (≤33 lb): 30 mg twice daily (5 mL of 6 mg/mL suspension)
• >15-23 kg (33-51 lb): 45 mg twice daily (7.5 mL of suspension)
• >23-40 kg (51-88 lb): 60 mg twice daily (10 mL of suspension)
• >40 kg (>88 lb): 75 mg twice daily (12.5 mL of suspension)

Infants (0-11 months)

• Infants 9-11 months: 3.5 mg/kg per dose twice daily for 5 days 1, 2
• Term infants 0-8 months: 3 mg/kg per dose twice daily for 5 days 1, 2
• Oseltamivir is FDA-approved for infants as young as 2 weeks of age 1, 2

Preterm Infants - Postmenstrual Age-Based Dosing

Preterm infants require lower doses due to immature renal function: 1, 3

• <38 weeks postmenstrual age: 1.0 mg/kg twice daily
• 38-40 weeks postmenstrual age: 1.5 mg/kg twice daily
• >40 weeks postmenstrual age: 3.0 mg/kg twice daily

---

Prophylaxis Dosing

Adults and Adolescents (≥13 years)

• 75 mg orally once daily 1, 2
• Duration: 10 days following close contact with infected individual 1
• Up to 6 weeks during community outbreak 1
• Immunocompromised patients may continue for up to 12 weeks 2

Pediatric Patients (≥12 months) - Weight-Based Dosing

All doses given once daily for 10 days: 1, 2

• ≤15 kg: 30 mg once daily
• >15-23 kg: 45 mg once daily
• >23-40 kg: 60 mg once daily
• >40 kg: 75 mg once daily

Infants (3-11 months)

• 3.5 mg/kg once daily for 10 days (for 9-11 month olds) 1, 3
• 3 mg/kg once daily for 10 days (for 3-8 month olds) 1
• Not recommended for infants <3 months unless situation judged critical due to limited safety data 1, 3

---

Renal Impairment Adjustments

Dose adjustment is mandatory for patients with creatinine clearance 10-30 mL/min: 1, 3

Treatment

• 75 mg once daily for 5 days (instead of twice daily) 1, 2

Prophylaxis

• 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 total doses) 1, 3

---

Formulations and Administration

Available Formulations

• Capsules: 30 mg, 45 mg, 75 mg 1, 2
• Oral suspension: 6 mg/mL when reconstituted from powder 1, 2
• If commercial suspension unavailable, pharmacies can compound suspension per package label instructions (final concentration 6 mg/mL) 1

Administration Pearls

• Administer with food to reduce nausea and vomiting, the most common adverse effects 1, 3, 6
• Gastrointestinal effects are typically mild, transient, and occur primarily with first dosing 6, 4
• Discontinuation rate due to adverse effects is low (1.8%) 4

---

Critical Clinical Considerations

Timing of Initiation

• Maximum benefit occurs when treatment starts within 48 hours of symptom onset 1, 2, 4
• Earlier initiation provides progressively greater benefit: treatment within 12 hours reduces illness duration by 74.6 hours compared to treatment at 48 hours 4
• In ICU patients with H1N1, oseltamivir may improve survival when started within 5 days of symptom onset 7

Antiviral Resistance Patterns

• Current influenza A (H3N2) and B strains show sensitivity to oseltamivir 1
• High-level resistance exists to amantadine and rimantadine; these agents should not be used 1
• Zanamivir remains an alternative for patients ≥7 years (treatment) or ≥5 years (prophylaxis), though more difficult to administer 1

Common Pitfalls to Avoid

• Do not use live attenuated influenza vaccine (LAIV) within 48 hours before oseltamivir or for 14 days after LAIV vaccination 3
• Do not extend treatment beyond 5 days in general populations - no evidence supports longer duration except possibly in critically ill H1N1 ICU patients 7
• Do not use double-dose oseltamivir (150 mg twice daily) - no survival benefit demonstrated 7
• Remember to adjust dose for renal impairment to avoid toxicity 1, 3

Special Populations

• Elderly and high-risk patients (chronic cardiac/respiratory disease) benefit similarly to healthy adults 8
• Oseltamivir reduces duration of acute febrile illness by 44% in cardiac disease patients and 30% in COPD patients 8
• Efficacy is similar for influenza A and B infections 8